Shares of BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $251.70.
BGNE has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on shares of BeiGene from $184.00 to $186.00 and gave the stock an "overweight" rating in a report on Tuesday, March 19th. Sanford C. Bernstein cut their price target on shares of BeiGene from $196.00 to $161.00 and set a "market perform" rating on the stock in a report on Wednesday, March 27th. Bank of America cut their price target on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a report on Monday, April 8th. Finally, Guggenheim cut their price target on shares of BeiGene from $350.00 to $345.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th.
Check Out Our Latest Report on BeiGene
BeiGene Trading Down 1.8 %
Shares of BeiGene stock traded down $2.44 on Friday, hitting $129.52. The stock had a trading volume of 296,406 shares, compared to its average volume of 260,071. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06. BeiGene has a one year low of $126.97 and a one year high of $266.67. The stock has a market cap of $12.39 billion, a price-to-earnings ratio of -15.24 and a beta of 0.61. The stock's 50-day simple moving average is $155.43 and its two-hundred day simple moving average is $168.61.
BeiGene (NASDAQ:BGNE - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The firm had revenue of $634.40 million for the quarter, compared to analysts' expectations of $632.52 million. During the same quarter last year, the business earned ($4.29) earnings per share. The business's revenue was up 66.9% on a year-over-year basis. As a group, sell-side analysts predict that BeiGene will post -8.87 EPS for the current year.
Insider Buying and Selling at BeiGene
In other BeiGene news, CEO John Oyler sold 37,668 shares of the firm's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the transaction, the chief executive officer now owns 12,332 shares of the company's stock, valued at $2,022,694.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other BeiGene news, CEO John Oyler sold 37,668 shares of the firm's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the transaction, the chief executive officer now owns 12,332 shares of the company's stock, valued at $2,022,694.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,781 shares of company stock valued at $10,222,381. 7.40% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On BeiGene
Several large investors have recently modified their holdings of the stock. LVW Advisors LLC raised its position in shares of BeiGene by 50.2% in the 1st quarter. LVW Advisors LLC now owns 1,957 shares of the company's stock worth $306,000 after purchasing an additional 654 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company's stock worth $38,658,000 after purchasing an additional 136,458 shares during the last quarter. Virtu Financial LLC raised its position in shares of BeiGene by 94.2% in the 4th quarter. Virtu Financial LLC now owns 5,319 shares of the company's stock worth $959,000 after purchasing an additional 2,580 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of BeiGene in the 4th quarter worth about $2,309,000. Finally, Virtus ETF Advisers LLC raised its position in shares of BeiGene by 19.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 1,739 shares of the company's stock worth $314,000 after purchasing an additional 280 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company's stock.
About BeiGene
(
Get Free ReportBeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Featured Stories
Before you consider BeiGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeiGene wasn't on the list.
While BeiGene currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
